Publication Brief
Understanding astrocyte biology is essential for advancing translational neuroscience. GFAP has emerged as a leading biomarker of CNS injury, and Simoa® technology now enables its ultra-sensitive detection directly in mouse plasma and serum—bridging preclinical research with human clinical insights.
The publication brief explains how the Simoa Mammalian GFAP Assay further supports earlier detection, clearer mechanistic understanding, and more predictive therapeutic translation across neurodegenerative and neuroinflammatory disease models.
Simoa is expanding what’s possible in translational and real-world research. Download the publication brief now.